Market Cap 33.75B
Revenue (ttm) 1.70B
Net Income (ttm) -190.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -11.22%
Debt to Equity Ratio 0.06
Volume 1,369,700
Avg Vol 1,402,186
Day's Range N/A - N/A
Shares Out 138.01M
Stochastic %K 94%
Beta 1.63
Analysts Strong Sell
Price Target $235.58

Company Profile

Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples und...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 650 980 9190
Address:
13011 McCallen Pass, Building A Suite 100, Austin, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 1:53 AM
Actionable Trade Alert for $NTRA: Market Context: $NTRA closed at $242.06, approaching the 60D high of $243.73. The RSI is at 87.84, indicating an overbought condition, suggesting potential for a pullback. The MA30 and MA50 are significantly lower at 212.37 and 196.33, respectively, indicating a strong upward trend but also highlighting potential volatility. Directional Bias: The current price is near the high of the 60-day range, which could lead to a reversal. However, the strong upward momentum suggests a cautious bullish stance. Trade Plan: - Suggested Entry: $242.06 - Stop Loss: $235.26 (below recent support, approximately 3% downside) - Take Profit Targets: 1. Target 1: $250.00 (3.3% gain) 2. Target 2: $260.00 (7.4% gain) 3. Target 3: $284.00 (17.3% gain) This plan aims for a minimum of 17% ROI on the third target while managing risk with a reasonable stop loss. Monitor RSI for signs of reversal before entering. https://privateprofiteers.com
0 · Reply
invisiblesurfer
invisiblesurfer Dec. 5 at 1:50 PM
$NTRA acquired Foresight DX, enters lymphoma and potentially blood tumours space. https://www.businesswire.com/news/home/20251205184980/en/Natera-Acquires-Foresight-Diagnostics?utm_campaign=shareaholic&utm_medium=copy_link&utm_source=bookmark
0 · Reply
Estimize
Estimize Dec. 4 at 9:00 PM
Wall St is expecting -0.50 EPS for $NTRA Q4 [Reporting 03/04 AMC] http://www.estimize.com/intro/ntra?chart=historical&metric_name=eps&utm_c
0 · Reply
oaksapollo
oaksapollo Dec. 4 at 4:56 PM
$GH and $NTRA have a combined cap of nearly $50B now, while shares of poor neglected $LUCD can be purchased for $1 ($140M cap). Pretty crazy given they are the only player in the $30B esophageal cancer screening space. There is no questioning the TAM - pricing has already been set by CMS at $1932 and there are good data defining the screening population at 30M people (per ACG guidance). And yes, I know, their history is not glamorous. IPO’d at $14 and traded to pennies, but after a long journey they are finally on the cusp of broad coverage with all of the GI community rooting for them. Test volume and revenue will scale quickly.
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Dec. 3 at 10:41 AM
$NTRA $NTSK $NU $NUAI $NUE Cycle Trading Signal plugged into AI 🔥 lists 🔥 Undeniable Accuracy 🔥
0 · Reply
erevnon
erevnon Dec. 2 at 6:30 PM
Morgan Stanley maintains Natera $NTRA at Overweight and raises the price target from $220 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
JarvisFlow
JarvisFlow Dec. 2 at 5:49 PM
Morgan Stanley updates rating for Natera ( $NTRA ) to Overweight, target set at 220 → 265.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 2 at 2:25 PM
$NTRA Current Stock Price: $234.28 Contracts to trade: $230 NTRA Dec 19 2025 Call Entry: $10.84 Exit: $18.75 ROI: 73% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 1 at 11:42 AM
$NTRA Share Price: $238.72 Contract Selected: May 15, 2026 $240 Calls Buy Zone: $23.26 – $28.73 Target Zone: $42.20 – $51.58 Potential Upside: 71% ROI Time to Expiration: 164 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
glynch2001
glynch2001 Dec. 1 at 12:42 AM
$NTRA $GRAL $PSNL $TWST starting to watch. Am I missing any others?
1 · Reply
Latest News on NTRA
Natera Acquires Foresight Diagnostics

Dec 5, 2025, 7:00 AM EST - 1 day ago

Natera Acquires Foresight Diagnostics


Natera Integrates with Flatiron Health's OncoEMR® Platform

Nov 12, 2025, 8:00 AM EST - 24 days ago

Natera Integrates with Flatiron Health's OncoEMR® Platform


Natera, Inc. (NTRA) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 8:36 PM EST - 4 weeks ago

Natera, Inc. (NTRA) Q3 2025 Earnings Call Transcript


Natera Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 4:05 PM EST - 4 weeks ago

Natera Reports Third Quarter 2025 Financial Results


Natera to Report its Third Quarter Results on November 6, 2025

Oct 30, 2025, 7:00 AM EDT - 5 weeks ago

Natera to Report its Third Quarter Results on November 6, 2025


Natera Named to Fast Company's Next Big Things in Tech List

Oct 16, 2025, 8:00 AM EDT - 7 weeks ago

Natera Named to Fast Company's Next Big Things in Tech List


Can Natera Stock Reach $500?

Sep 15, 2025, 10:10 AM EDT - 2 months ago

Can Natera Stock Reach $500?


Natera Provides Update on Patent Litigation with NeoGenomics

Aug 29, 2025, 8:18 AM EDT - 3 months ago

Natera Provides Update on Patent Litigation with NeoGenomics


Natera, Inc. (NTRA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 10:43 PM EDT - 4 months ago

Natera, Inc. (NTRA) Q2 2025 Earnings Call Transcript


Natera (NTRA) Q2 Revenue Jumps 32%

Aug 7, 2025, 5:54 PM EDT - 4 months ago

Natera (NTRA) Q2 Revenue Jumps 32%


Natera Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 4 months ago

Natera Reports Second Quarter 2025 Financial Results


Natera to Report Its Second Quarter Results on August 7, 2025

Jul 31, 2025, 7:00 AM EDT - 4 months ago

Natera to Report Its Second Quarter Results on August 7, 2025


Natera Announces Medicare Coverage for Signatera™ Genome

Jun 4, 2025, 7:00 AM EDT - 6 months ago

Natera Announces Medicare Coverage for Signatera™ Genome


Natera: The Clues In Q1 Earnings

May 16, 2025, 8:41 AM EDT - 7 months ago

Natera: The Clues In Q1 Earnings


Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript

May 8, 2025, 8:58 PM EDT - 7 months ago

Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript


Natera Reports First Quarter 2025 Financial Results

May 8, 2025, 4:05 PM EDT - 7 months ago

Natera Reports First Quarter 2025 Financial Results


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 1:53 AM
Actionable Trade Alert for $NTRA: Market Context: $NTRA closed at $242.06, approaching the 60D high of $243.73. The RSI is at 87.84, indicating an overbought condition, suggesting potential for a pullback. The MA30 and MA50 are significantly lower at 212.37 and 196.33, respectively, indicating a strong upward trend but also highlighting potential volatility. Directional Bias: The current price is near the high of the 60-day range, which could lead to a reversal. However, the strong upward momentum suggests a cautious bullish stance. Trade Plan: - Suggested Entry: $242.06 - Stop Loss: $235.26 (below recent support, approximately 3% downside) - Take Profit Targets: 1. Target 1: $250.00 (3.3% gain) 2. Target 2: $260.00 (7.4% gain) 3. Target 3: $284.00 (17.3% gain) This plan aims for a minimum of 17% ROI on the third target while managing risk with a reasonable stop loss. Monitor RSI for signs of reversal before entering. https://privateprofiteers.com
0 · Reply
invisiblesurfer
invisiblesurfer Dec. 5 at 1:50 PM
$NTRA acquired Foresight DX, enters lymphoma and potentially blood tumours space. https://www.businesswire.com/news/home/20251205184980/en/Natera-Acquires-Foresight-Diagnostics?utm_campaign=shareaholic&utm_medium=copy_link&utm_source=bookmark
0 · Reply
Estimize
Estimize Dec. 4 at 9:00 PM
Wall St is expecting -0.50 EPS for $NTRA Q4 [Reporting 03/04 AMC] http://www.estimize.com/intro/ntra?chart=historical&metric_name=eps&utm_c
0 · Reply
oaksapollo
oaksapollo Dec. 4 at 4:56 PM
$GH and $NTRA have a combined cap of nearly $50B now, while shares of poor neglected $LUCD can be purchased for $1 ($140M cap). Pretty crazy given they are the only player in the $30B esophageal cancer screening space. There is no questioning the TAM - pricing has already been set by CMS at $1932 and there are good data defining the screening population at 30M people (per ACG guidance). And yes, I know, their history is not glamorous. IPO’d at $14 and traded to pennies, but after a long journey they are finally on the cusp of broad coverage with all of the GI community rooting for them. Test volume and revenue will scale quickly.
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Dec. 3 at 10:41 AM
$NTRA $NTSK $NU $NUAI $NUE Cycle Trading Signal plugged into AI 🔥 lists 🔥 Undeniable Accuracy 🔥
0 · Reply
erevnon
erevnon Dec. 2 at 6:30 PM
Morgan Stanley maintains Natera $NTRA at Overweight and raises the price target from $220 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
JarvisFlow
JarvisFlow Dec. 2 at 5:49 PM
Morgan Stanley updates rating for Natera ( $NTRA ) to Overweight, target set at 220 → 265.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 2 at 2:25 PM
$NTRA Current Stock Price: $234.28 Contracts to trade: $230 NTRA Dec 19 2025 Call Entry: $10.84 Exit: $18.75 ROI: 73% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 1 at 11:42 AM
$NTRA Share Price: $238.72 Contract Selected: May 15, 2026 $240 Calls Buy Zone: $23.26 – $28.73 Target Zone: $42.20 – $51.58 Potential Upside: 71% ROI Time to Expiration: 164 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
glynch2001
glynch2001 Dec. 1 at 12:42 AM
$NTRA $GRAL $PSNL $TWST starting to watch. Am I missing any others?
1 · Reply
PolycarpFX
PolycarpFX Nov. 29 at 3:57 PM
$NTRA Natera Inc, a top holding of legendary investor Stanley Druckenmillers fund.
0 · Reply
MaverikIT
MaverikIT Nov. 26 at 3:44 PM
$NTRA +2.72 - been lovely
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 26 at 2:23 PM
$NTRA Share Price: $236.34 Contract Selected: May 15, 2026 $240 Calls Buy Zone: $23.26 – $28.73 Target Zone: $42.95 – $52.49 Potential Upside: 74% ROI Time to Expiration: 169 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
erevnon
erevnon Nov. 25 at 3:47 PM
JP Morgan maintains Natera $NTRA at Overweight and raises the price target from $240 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
JarvisFlow
JarvisFlow Nov. 25 at 3:20 PM
JP Morgan updates rating for Natera ( $NTRA ) to Overweight, target set at 240 → 250.
0 · Reply
JasonCO
JasonCO Nov. 24 at 7:00 PM
$NTRA unstoppable force
0 · Reply
WAJeff
WAJeff Nov. 24 at 6:00 PM
0 · Reply
ScreenerIQ
ScreenerIQ Nov. 23 at 5:49 PM
Some Stocks showing strong relative strength. Filtered on '5-Day Return'. Please DYOResearch. Some examples: $EYPT $MNPR $NTRA $DY #StockMarket #investing #Trading
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 23 at 3:35 PM
0 · Reply
Doozio
Doozio Nov. 21 at 7:57 PM
$NTRA Druckenmiller walking into da weekend during 🐒🍌🧠⏰♾️
0 · Reply
WAJeff
WAJeff Nov. 21 at 7:07 PM
$NTRA $235.71 ath
0 · Reply
MD109
MD109 Nov. 21 at 5:01 PM
$PSNL Using “liquid biopsy” for cancer screening and monitoring (MRD) is now front and center - not just at medical conferences but also in the investment arena (CNBC etc). $PSNL is perfectly positioned and has been working hard for 10+ years to capitalize on this moment. As I’ve said many times - hold your shares tight and if you’re able to accumulate more while it trades at under a $1 billion market cap, I believe you will be rewarded long term. If you’re new to the Personalis story, please note that it’s still very early days. Look at $NTRA - its market cap is over $32 billion and many institutional investors are just now discovering the company and building large positions. Now imagine you were buying Natera shares years ago at under $10 before the institutions took notice. That’s where we are right now with Personalis. Big opportunity for those building positions in Personalis at these levels, prior to multiple significant catalysts next year.
2 · Reply